Dried Blood Spot Collection to Revolutionise Postpartum Depression Screening

11 July

Brisbane, Australia – July 11, 2025 – Ketim Technologies has received its first shipment of dried blood spot (DBS) collection devices from Swedish partner Capitainer, marking a major step forward in the company’s mission to expand access to early detection of postpartum depression (PPD).

The DBS technology will be evaluated alongside traditional whole blood collection methods as part of a newly submitted prospective clinical trial at the Mater Hospital. The study will recruit pregnant women to assess the usability, patient preferences, and effectiveness of DBS for capturing the company’s patented novel biomarkers for PPD.

By enabling sample collection from a single drop of blood, DBS offers a convenient, minimally invasive option that can be mailed from anywhere — making it particularly valuable for reaching women in remote communities or those unable to access phlebotomy services after birth.

“This is a huge step toward democratising maternal mental health care,” said Dr. Clarissa Yates, CEO and Founder of Ketim Technologies. “If we can provide a DBS point-of-care test for women during pregnancy or after birth, we can overcome many barriers to care and ensure timely access to screening for those who need it most.”

The DBS project builds on Ketim Technologies’ biomarker-driven, AI-powered platform for predicting risk of PPD before symptom onset, further strengthening the company’s focus on precision diagnostics in women’s mental health.

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au